A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
Boston Scientific Corporation
National Institutes of Health Clinical Center (CC)
University of Oklahoma
University College Cork
Peter MacCallum Cancer Centre, Australia
Duke University
Werewolf Therapeutics, Inc.
Novartis
HistoSonics, Inc.
Bristol-Myers Squibb
AstraZeneca
University of Washington
M.D. Anderson Cancer Center
University of Arizona
Loyola University
Exelixis
Exelixis
Medicine Invention Design, Inc
AbbVie
University College, London
DEKA Biosciences
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc
University Teaching Hospital Hall in Tirol
Exelixis
UNICANCER
Actuate Therapeutics Inc.
Salubris Biotherapeutics Inc
AO GENERIUM
SillaJen, Inc.